Jan 05, 2021 / 07:25PM GMT
Matthew Carlisle Sykes - Goldman Sachs Group, Inc., Research Division - Research Analyst
Good afternoon, everyone, and Happy New Year. I'm Matt Sykes, the life science tools and diagnostics analyst for Goldman Sachs, and I have the pleasure of welcoming Mike McMullen, CEO; and Bob McMahon, CFO of Agilent, here today. Mike and Bob, thanks so much for joining us today. We really appreciate the time.
I thought I'd let you guys set the stage for us in the first few minutes and talk about the year review for Agilent. What were some of the challenges and opportunities presented by COVID? And then what parts of the business are you most excited about for 2021? And kind of how did the 2020 finish up? And what does the momentum look like as we head into the new year?
Michael R. McMullen - Agilent Technologies, Inc. - CEO, President & Director
Sure, Matt. And first of all, thanks for the invitation to join today's conference, and Happy New Year to the audience, and thank you for joining us here as well.
So 2020, as we all know, will go down as a
Agilent Technologies Inc at Goldman Sachs Healthcare CEOs Unscripted Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot